Expert Insights & Commentary
BLOG
The South Florida Venture Tech Chronicle Blog goes beyond the headlines.
Here, founders, investors, and industry experts share their perspectives on emerging technologies, investment strategies, and the challenges shaping our innovation ecosystem.
Expect thought leadership, data-driven opinions, and long-form features that deepen understanding of where tech is headed next.
AMPERA Unveils 3D-Printed Nuclear Reactor Module, Marking a Major Manufacturing Milestone
Palm Beach Gardens-based AMPERA has unveiled what it describes as the world's first full-scale, fully 3D-printed nuclear reactor module. While the reactor is not yet operational, the milestone showcases how advanced manufacturing and modular reactor design could help accelerate the future of clean, reliable nuclear energy.
GBI Biomanufacturing Expands in South Florida, Signaling a Turning Point for the Region’s Life Sciences Infrastructure
GBI Biomanufacturing is entering a major new growth phase in South Florida, marked by a 40,000-square-foot facility expansion, a $26 million infrastructure investment, and a strategic ramp-up in stem cell manufacturing capacity toward one million doses annually. With new President Jesse McCool at the helm and recognition as BioFlorida’s 2025 Manufacturer of the Year, the company is strengthening its role as a key biomanufacturing anchor in the region’s evolving life sciences ecosystem. Its expanded cGMP facility integrates advanced biologics production, fill-finish capabilities, and end-to-end process development, positioning GBI at the center of South Florida’s shift from emerging biotech market to operational manufacturing hub.
Lupin to Invest $250 Million in New Pharmaceutical Manufacturing Facility in Coral Springs
Global pharmaceutical company Lupin Limited is investing $250 million to build a state-of-the-art manufacturing facility in Coral Springs, Florida. The new 70,000-square-foot site will produce over 25 critical respiratory medicines, including life-saving albuterol inhalers, and is expected to create more than 200 skilled jobs by 2030. This expansion strengthens domestic drug manufacturing, supply chain resilience, and South Florida’s position as a hub for life sciences innovation.